Mosquitoes Bite Some People (Credit-Freepik)
Mosquitoes are a big part of the ecosystem, but often are a nuisance as they bite and feed off of us. Their bites cause itchy red bumps and spread infections and allergies in our bodies. But have you ever wondered why they bite certain people more than others? While some people are plagued by mosquito bites, others barely notice them. Here are some interesting facts about mosquitoes that you must know about!
1. Carbon Dioxide:
Mosquitoes are attracted to a certain smell that emits from the human body that is present in the human skin and sweat, mosquitoes can sense the carbon dioxide or CO2 we breathe out. The more active you are, the more CO2 you emit and the more mosquitoes will be attracted to you. Researchers are still investigating the cause of the variation of body odour that brings them to you, possibly genetics or certain bacteria. The unique combination of sweat and skin bacteria creates a scent that mosquitoes find irresistible. Some chemicals in sweat, like lactic acid and ammonia, are especially attractive to them.
2. Colours
While the reason isn't fully understood, mosquitoes seem to be drawn to dark colours like black more than lighter ones. So, ditch the dark outfit next time you're in mosquito territory. It has been noted that mosquitoes are more likely to leave lighter colours alone.
3. Heat and Vapour
Mosquitoes can detect your body's heat and water vapour, acting like a beacon guiding them right to you. So next time you're feeling sweaty, be aware you might be attracting a lot of mosquitoes. If you are working out or doing something that is making you sweat and your body heat rise, the mosquitoes nearby will be instantly attracted to you. Even mosquitoes are careful about who they pick as a host, some studies even suggest that they like a certain body temperature to feed off of.
An interesting fact about mosquitoes is that they can learn to like a host. They have their own preferences and if they meet a certain person who fits their criteria they might be the next host they move onto. In an older study, it showed that 20 per cent of people with mosquito-borne diseases accounted for 80 per cent of diseases transmitted in the population. They suggest that they only bite a certain set of people within the population.
4. Other factors:
Studies suggest mosquitoes might learn to prefer certain people based on things like what you've been drinking. In a 2002 study, there could be many reasons they like alcohol to making your body temperature high etc. Even pregnant women seem to be extra attractive to them due to higher body temperature and CO2 output.
Metabolic dysfunction-associated steatotic liver disease (MASLD), previously called fatty liver disease, is becoming extremely common in people with type 2 diabetes in India.
Studies suggest that 50–70 percent of Indians with type 2 diabetes may have fatty liver, and a significant proportion can progress to inflammation, liver fibrosis, cirrhosis, or even liver cancer if the condition is not detected early. Because India already has one of the world’s largest populations with diabetes, MASLD is emerging as a major but under-recognized public health problem.
The recently published consensus guidelines developed by Indian experts aim to provide practical, India-specific recommendations for diagnosing and managing MASLD in people with type 2 diabetes.
In fact, these are the first global guidelines for MASLD and type 2 diabetes, albeit restricted to India. This matters because most existing international guidance—including from organizations such as the American Diabetes Association—is largely based on evidence and healthcare systems in high-income Western countries. These recommendations often assume easy access to expensive diagnostic tests and medications, which may not always be feasible in India.
In India, healthcare costs are frequently paid out-of-pocket by patients. Advanced imaging tests or newer medications can therefore be unaffordable for many people.
The Indian consensus addresses this reality by recommending step-wise and cost-effective screening strategies, beginning with simple clinical risk assessment and basic laboratory tests, followed by non-invasive fibrosis scoring tools and ultrasound when appropriate. This approach helps identify high-risk individuals without overburdening patients or the healthcare system.
Another important reason these guidelines matter is that Asian Indians have a unique metabolic profile. Compared with Western populations, Indians often develop diabetes and fatty liver at younger ages and lower body weight, partly because of higher abdominal fat and insulin resistance. Therefore, early screening for liver disease in people with diabetes becomes particularly important in India.
Dietary recommendations are also adapted to local eating patterns. Instead of focusing on Western dietary models, the guidelines emphasize reducing refined carbohydrates, excess sugars, and unhealthy fats common in Indian diets while promoting traditional, healthier foods, whole grains, legumes, and increased physical activity.
In simple terms, these India-specific guidelines aim to ensure that more patients with diabetes are screened early, treated appropriately, and protected from severe liver complications, using strategies that are practical, affordable, and suited to the realities of the Indian healthcare system.
Guidelines for MASLD developed in Western countries provide important scientific guidance, but they are often designed for healthcare systems with greater resources and different patient characteristics. The Indian consensus recommendations differ in several key ways to make them more suitable for local populations and healthcare settings.
First, screening strategies are more pragmatic and cost-conscious. Western guidelines often recommend advanced imaging tests or specialized biomarkers to assess liver fat and fibrosis. However, these tests can be expensive and not widely available in many parts of India.
The Indian recommendations emphasize simple, widely available tools—such as routine blood tests and non-invasive fibrosis scoring systems—before considering more advanced imaging. This stepwise approach ensures that patients who are most at risk are identified while keeping costs manageable.
Second, the guidelines recognize the unique metabolic risk profile of Asian Indians. Compared with Western populations, Indians tend to develop metabolic diseases such as type 2 diabetes and fatty liver at younger ages and lower body mass index (BMI). Abdominal obesity and insulin resistance are particularly common.
Therefore, the Indian recommendations stress earlier and more vigilant screening for MASLD in people with diabetes, even if they are not severely obese.
Third, treatment priorities differ because of affordability and access to medications. Western guidelines may emphasize newer and often expensive drugs that show benefits for fatty liver disease. While these therapies can be effective, they may not be accessible to many patients in low- and middle-income countries.
The Indian consensus places stronger emphasis on lifestyle interventions, weight reduction, improved diet, and physical activity as the foundation of treatment, while suggesting pharmacotherapy selectively based on evidence, availability, and cost.
Fourth, perhaps the most important difference, dietary advice is culturally tailored. Western guidelines typically discuss Mediterranean-style diets.
In contrast, the Indian recommendations translate healthy eating principles into Indian dietary patterns, focusing on reducing refined carbohydrates, sugar-sweetened foods, and excess saturated fats while promoting whole grains, pulses, vegetables, and traditional balanced meals.
Finally, the Indian document highlights the need for public health awareness and primary care involvement, since a large proportion of patients with diabetes are managed outside specialized centers.
Overall, the key difference is that while Western guidelines provide strong scientific foundations, the Indian recommendations adapt those principles to local realities.
Credits: Wikimedia Commons and Instagram
Bristol Palin, an American real estate agent, who was a former public speaker and reality television personality started experiencing facial paralysis over a tear ago. On March 9, her 35-year-old daughter Sarah Palin posted a video on her Instagram Stories that shared an update on her ongoing health struggles. The story revealed that she is now considering plastic surgery to fix her paralysis.
"I am going to have a consultation today with a plastic surgeon in Austin," she said. "I have read that she specializes in facial paralysis type stuff so we will see what she says."
She also said, "Prayers because maybe she can help mostly with this eye," while pointing to her left eye. "When I smile or when I am expressive, it closes. I don't really care about my crooked mouth but my eye...so embarrassing to me. I feel like I should wear an eyepatch or something."
She went on to say, "It looks crazy and I just feel like I cannot even smile because it just closes. So maybe she can do some Botox or maybe there is some options with surgery. So we will see. Maybe she ca help with this eye or just the overall symmetry."
She also said that she had just returned from Alaska, where she visited another specialist who does her facial nerve blocks to help her paralysis. She also posted another update on her Instagram Stories and said that her consultation went well and that she will be sharing the information with her followers soon.
It was in January 2025, when she revealed her facial paralysis on Instagram. "I woke up nine days ago with a little weird sensation in my face. My mouth was pulling this way and it just felt a little off. So I went, looked in the mirror. I'm like 'Wow. This is looking a little weird. I feel like everything is pulling to the left."
She said that hours later her condition got worse and the left side of her face was having a "delayed" reaction.
Read: Why Does Your BBL Smell? Doctor Explains 4 Reasons That Could Cause It
As per a 2020 study published in the Indian Journal of Plastic Surgery, botulinum toxin (Botox) injections are helpful and are minimally invasive technique to restore facial symmetry. However, the study noted that a "surprisingly small minority of aesthetic injectors treat this condition."

The study also gives a case study of a patient with longstanding facial nerve paralysis after resection of an osteogenic sarcoma, before and after two weeks after first treatment with botulinum toxin. The improvements could be seen in mentalis synkinesis, more symmetrical smile, and improved eye apertures on animation.
It is an FDA-approved, injectable neurotoxin derived from Clostridium botulinum bacteria. It temporarily relaxes muscles by blocking nerve signals, commonly used to smooth dynamic wrinkles and treat medical conditions like chronic migraines, excessive sweating, and muscle spasms. Its effects last from three to four months.
Botox prevents the release of a neurotransmitter that signals muscles to contract, causing them to relax and soften wrinkles. Results typically appear in 3 to 14 days.
Credits: Canva and iStock
The US Food and Drug Administration approved leucovorin for cerebral folate deficiency in the receptor 1 gene, a rare genetic condition. However, last year, in September, this drug was noted as the possible and potential treatment for children with autism. The Trump administration noted that Tylenol may be triggering autism in children when is consumed by pregnant mothers. The same conference touted this drug as a potential treatment, while not enough scientific evidence was there to support the claim. Yet, many parents looked for the prescription to support their children.
Health and Me also reported a story of a mother who looked for the drug for her three-year-old son. Another case of four-year-old Jose Morales-Ortiz, who struggled to speak even two-word sentences. As per a CNN report, he was diagnosed with severe autism and rarely responded when someone called his name.
However, something changed, in early summers, he began telling his guardian Keith Joyce about the conversation with his classmates and answering follow-up questions. For Keith, it was a moment of joy. It was also the first time Keith had a conversation with him.
Joyce believes the change began after Jose started taking leucovorin, a medication originally approved to reduce the side effects of certain chemotherapy drugs. Now, researchers are investigating whether the drug may help some children with autism—particularly those with a condition known as cerebral folate deficiency.
However, scientists caution that while early studies are promising, the evidence is still limited and the treatment remains controversial.
Leucovorin, also known as folinic acid, is a biologically active form of vitamin B9 or folate. Unlike standard folic acid supplements, it does not require the body to convert it into an active form before it can be used. Due to this very feature, it can bypass certain metabolic steps and deliver folate more directly to the cells.
It is a high-dose B vitamin, which is commonly used as a treatment to counteract the side effects of chemotherapy. It has been approved by the FDA for cerebral folate deficiency in the receptor 1 gene. The disease is rare and fewer than 50 cases have been identified worldwide. FDA Commissioner Dr Marty Makary called this approval "a significant milestone" for patients with the condition.
Doctors have used the drug for several purposes, which also include:
Recently, scientists began exploring whether leucovorin could also help certain neurological conditions.
Read: Leucovorin Approved By FDA But For A Rare Genetic Disease, Not For Autism
Folate is essential for brain development and neural function.
It helps in:
During pregnancy, folate is so critical that many countries fortify foods with folic acid to prevent birth defects such as neural tube defects.
However, in some children, the issue may not be a lack of folate in the diet—but a problem with how folate reaches the brain.
In 2005, researchers discovered an unusual phenomenon in some children with developmental disorders.
Although their blood folate levels were normal, their brain folate levels were extremely low.
The reason appeared to be autoantibodies—immune proteins that mistakenly attack the body’s own tissues. In this case, the antibodies targeted folate receptor alpha, the protein responsible for transporting folate across the blood-brain barrier.
This condition is called cerebral folate deficiency.
Researchers also developed a diagnostic blood test called the Folate Receptor Autoantibody Test (FRAT) to detect these antibodies.
It could work in such a case because it is able to bypass the blocked folate receptors. It does not rely on the usual transport system and is able to enter the brain through alternative transport pathways, which allow neurons to access the folate they need. Scientists also believe that this could improve neurotransmitter production, support neural communication, and enhance brain metabolism in certain children.
Some clinical studies have suggested that leucovorin may improve language and communication skills in certain children with autism.
However, the results have been mixed.
Some studies have found only modest improvements, and large placebo-controlled trials—considered the gold standard in medical research—are still lacking.
Because autism is a complex spectrum condition with many biological pathways involved, researchers emphasize that no single medication is likely to work for every child.
The growing interest in leucovorin reflects a broader shift in autism research: looking for biological subtypes of the condition that might respond to targeted treatments.
If cerebral folate deficiency proves to be one of those subtypes, leucovorin could become an important therapy for a specific group of children.
But scientists emphasize that autism is highly complex. “There’s no autism pill,” many researchers say.
© 2024 Bennett, Coleman & Company Limited